These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 6813994)

  • 1. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
    Austen DE; Smith JK
    Thromb Haemost; 1982 Aug; 48(1):46-8. PubMed ID: 6813994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
    Prowse CV; Griffin B; Pepper DS; Dickson AJ; McQuillan TA; Dickson IH; Foster PR
    Thromb Haemost; 1981 Oct; 46(3):597-601. PubMed ID: 6797090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction of the factor VIII/von Willebrand factor complex (VIII/vWf), with guanidinium-derivatized matrices.
    Saundry RH; Savidge GF
    Bioseparation; 1991; 2(3):177-86. PubMed ID: 1368084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Factor VIII preparations of varying purity-examination of physico-chemical parameters (author's transl)].
    Vukovich T; Koller E; Doleschel W; Mayr WR
    Wien Klin Wochenschr; 1980; 92(11):385-91. PubMed ID: 6775418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative protein chemistry studies on Factor VIII concentrates].
    Kienast K; Trobisch H
    Arzneimittelforschung; 1984; 34(8):895-900. PubMed ID: 6437415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of hepatitis B antigen and isoagglutinins in clinical concentrates of factor VIII and prothrombin complex.
    Wickerhauser M
    Dev Biol Stand; 1974; 27():172-7. PubMed ID: 4463121
    [No Abstract]   [Full Text] [Related]  

  • 9. [Factor VIII concentrate, highly purified and heated in solution (author's transl)].
    Heimburger N; Schwinn H; Gratz P; Lüben G; Kumpe G; Herchenhan B
    Arzneimittelforschung; 1981; 31(4):619-22. PubMed ID: 6788045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoaffinity purification of factor VIII.
    Weinstein RE
    Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency].
    Yoshioka A
    Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996
    [No Abstract]   [Full Text] [Related]  

  • 12. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
    Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity purification of plasma proteins: characterization of six affinity matrices and their application for the isolation of human factor VIII.
    te Booy MP; Riethorst W; Faber A; Over J; König BW
    Thromb Haemost; 1989 Apr; 61(2):234-7. PubMed ID: 2501896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of hepatitis B surface antigen in commercially prepared plasma products.
    Hoofnagle JH; Gerety RJ; Thiel J; Barker LF
    J Lab Clin Med; 1976 Jul; 88(1):102-13. PubMed ID: 932529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
    Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chromatographic separation of factor VIII on aminohexyl sepharose.
    Austen DE
    Br J Haematol; 1979 Dec; 43(4):669-74. PubMed ID: 526447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate.
    Hart H; Jones A; Cubie H; McIntosh RV; Cuthbertson B
    Vox Sang; 1994; 67 Suppl 1():51-5. PubMed ID: 8091738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.
    Lusher JM; Salzman PM
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):1-7. PubMed ID: 1965615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.